BioCentury | Aug 6, 2015
Product R&D

Impede a fever

...tetravalent vaccine against dengue virus envelope protein E (DENV_gp1) Preclinical NanoViricides Inc. Anti-dengue nanoviricides (DengiCide, DengueCide) Nanoviricides...
BioCentury | Nov 10, 2014
Financial News

NanoViricides financial update

...NanoViricides Inc. (NYSE-M:NNVC), West Haven, Conn. Business: Infectious Date announced: 2014-10-31 Note: NanoViricides filed a shelf...
BioCentury | Sep 25, 2014
Cover Story

Interrupting Ebola

...in multiple viruses, including Marburg BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX); NIH Will submit IND Nov. 2014 Nanoviricides...
...binding site of the virus on its cell surface receptor, to a nanomicelle flexible polymer NanoViricides Inc....
BioCentury | Sep 15, 2014
Financial News

NanoViricides completes warrant exercise

NanoViricides Inc. (NYSE-M:NNVC), West Haven, Conn. Business: Infectious Date completed: 2014-09-08 Type: Warrant exercise Raised: $7.5 million Shares: 2.1 million Price: $3.50 Shares after offering: 56.8 million Investor: Existing investors WIR Staff Infectious...
BioCentury | Sep 15, 2014
Product Development

Ebola realities

...Tokyo:4901) DoD Favipiravir (T-705) Viral RNA polymerase inhibitor Preclin NanoViricides Inc. (NYSE-M:NNVC) DoD Anti-Ebola virus nanoviricides Nanoviricides...
BioCentury | Aug 11, 2014
Finance

Highlights of weekly biotech stock moves

...Holdings Corp. (Tokyo:4901) Favipiravir (T-705) Viral RNA polymerase inhibitor Preclin NanoViricides Inc. (NYSE-M:NNVC) Anti-Ebola virus nanoviricides Nanoviricides...
BioCentury | Mar 10, 2014
Company News

NanoViricides infectious news

...Infectious disease company NanoViricides denied a rumor from a blog post on investment news website Seeking...
...close the matter who is "intent on acquiring NanoViricides for defensive purposes." Earlier this month, NanoViricides...
...Terminator, which NanoViricides said wrote a defamatory blog post on the company on Feb. 11. NanoViricides'...
BioCentury | Jan 27, 2014
Financial News

NanoViricides completes direct public offering

NanoViricides Inc. (NYSE-M:NNVC), West Haven, Conn. Business: Infectious Date completed: 1/21/14 Type: Direct public offering Raised: $20 million Units: 3.8 million Price: $5.25 (unit) Shares after offering: 53.9 million Placement agents: Chardan Capital Markets; Midtown...
BioCentury | Jan 27, 2014
Finance

Highlights of weekly biotech stock moves

...NanoString proposed to raise $55 million on Jan. 13, when its share price was $19.51. NanoViricides Inc....
...and a five-year warrant to purchase 0.65 shares, with each whole warrant exercisable at $6.05. NanoViricides'...
BioCentury | Jan 22, 2014
Financial News

NanoViricides raises $20 million in direct offering

...and Midtown Partners were placement agents. NanoViricides was off $1.06 (18%) to $4.99 on Tuesday. NanoViricides'...
Items per page:
1 - 10 of 56
BioCentury | Aug 6, 2015
Product R&D

Impede a fever

...tetravalent vaccine against dengue virus envelope protein E (DENV_gp1) Preclinical NanoViricides Inc. Anti-dengue nanoviricides (DengiCide, DengueCide) Nanoviricides...
BioCentury | Nov 10, 2014
Financial News

NanoViricides financial update

...NanoViricides Inc. (NYSE-M:NNVC), West Haven, Conn. Business: Infectious Date announced: 2014-10-31 Note: NanoViricides filed a shelf...
BioCentury | Sep 25, 2014
Cover Story

Interrupting Ebola

...in multiple viruses, including Marburg BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX); NIH Will submit IND Nov. 2014 Nanoviricides...
...binding site of the virus on its cell surface receptor, to a nanomicelle flexible polymer NanoViricides Inc....
BioCentury | Sep 15, 2014
Financial News

NanoViricides completes warrant exercise

NanoViricides Inc. (NYSE-M:NNVC), West Haven, Conn. Business: Infectious Date completed: 2014-09-08 Type: Warrant exercise Raised: $7.5 million Shares: 2.1 million Price: $3.50 Shares after offering: 56.8 million Investor: Existing investors WIR Staff Infectious...
BioCentury | Sep 15, 2014
Product Development

Ebola realities

...Tokyo:4901) DoD Favipiravir (T-705) Viral RNA polymerase inhibitor Preclin NanoViricides Inc. (NYSE-M:NNVC) DoD Anti-Ebola virus nanoviricides Nanoviricides...
BioCentury | Aug 11, 2014
Finance

Highlights of weekly biotech stock moves

...Holdings Corp. (Tokyo:4901) Favipiravir (T-705) Viral RNA polymerase inhibitor Preclin NanoViricides Inc. (NYSE-M:NNVC) Anti-Ebola virus nanoviricides Nanoviricides...
BioCentury | Mar 10, 2014
Company News

NanoViricides infectious news

...Infectious disease company NanoViricides denied a rumor from a blog post on investment news website Seeking...
...close the matter who is "intent on acquiring NanoViricides for defensive purposes." Earlier this month, NanoViricides...
...Terminator, which NanoViricides said wrote a defamatory blog post on the company on Feb. 11. NanoViricides'...
BioCentury | Jan 27, 2014
Financial News

NanoViricides completes direct public offering

NanoViricides Inc. (NYSE-M:NNVC), West Haven, Conn. Business: Infectious Date completed: 1/21/14 Type: Direct public offering Raised: $20 million Units: 3.8 million Price: $5.25 (unit) Shares after offering: 53.9 million Placement agents: Chardan Capital Markets; Midtown...
BioCentury | Jan 27, 2014
Finance

Highlights of weekly biotech stock moves

...NanoString proposed to raise $55 million on Jan. 13, when its share price was $19.51. NanoViricides Inc....
...and a five-year warrant to purchase 0.65 shares, with each whole warrant exercisable at $6.05. NanoViricides'...
BioCentury | Jan 22, 2014
Financial News

NanoViricides raises $20 million in direct offering

...and Midtown Partners were placement agents. NanoViricides was off $1.06 (18%) to $4.99 on Tuesday. NanoViricides'...
Items per page:
1 - 10 of 56